Vaccines for melanoma: Design strategies and clinical results

Dermatologic Clinics

Volumn 16, Issue 2, 1998, Pages 269-275

  Bystryn, J C ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA VACCINE;

ADJUVANT THERAPY; DIAGNOSTIC APPROACH ROUTE; HLA SYSTEM; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0031901448     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70009-7     Document Type: Article

References (23)

1. J. Applebaum S. Reynolds J. Knispel Identification of melanoma antigens that are immunogenic in humans and expressed in vivo J Natl Cancer Inst 1998
2. D. Berd H. Maguire M. Mastrangelo Treatment of human melanoma with a hapten modified autologous vaccine J.-C. Bystryn S. Ferrone P. Livingston Specific Immunotherapy of Cancer with Vaccines Ann NY Acad Sci 690 1993 147 150
3. O. Bertier-Vergnes J. Potoukalian E. Leftheriotis Induction of IgG antibodies directed to a Mr 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates Cancer Res 54 1994 2433 2439
4. Bystryn J.-C. Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma associated antigens J Immunol 120 1978 96 101
5. Bystryn J.-C. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens J.-C. Bystryn S. Ferrone P. Livingston Specific Immunotherapy of Cancer with Vaccines Ann NY Acad Sci 690 1993 190 203
6. Bystryn J.-C. R. Oratz D. Roses Relation between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma Cancer 69 1992 1157 1164
7. Bystryn J.-C. R.L. Shapiro R. Oratz Cancer vaccines: Clinical applications: Partially purified tumor antigen vaccines V. DeVita S. Hellman S.A. Rosenberg Biologic Therapy of Cancer ed 2 1995 JB Lippincott Philadelphia 668 679
8. P. Coulie P. Weynets C. Muller Genes encoding for antigen recognition on human tumors by autologous cytolytic lymphocytes J.-C. Bystryn S. Ferrone P. Livingston Specific Immunotherapy of Cancer with Vaccines Ann NY Acad Sci 690 1993 113 119
9. S. Ferrone Human tumor associated antigen mimicry by anti-idiotypic antibodies J.-C. Bystryn S. Ferrone P. Livingston Specific Immunotherapy of Cancer with Vaccines Ann NY Acad Sci 690 1993 214 221
10. B. Gaugler P. Van den Eynde B. Van der Bruggen Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T-lymphocytes J Exp Med 179 1994 921 930
11. P. Hersey Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma J.-C. Bystryn S. Ferrone P. Livingston Specific Immunotherapy of Cancer with Vaccines Ann NY Acad Sci 690 1993 167 177
12. P. Hersey H. Werkman A.E. Edwards Western blot analysis of serological responses following immunization with vaccinia viral lysates of melanoma cells Int J Cancer 46 1990 612 617
13. Y. Kawakami S. Eliyahu S. Kazuyasu Identification of the immunodominant peptides of MART-1 recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes J Exp Med 180 1994 347 352
14. P.O. Livingston Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines J.-C. Bystryn S. Ferrone P. Livingston Specific Immunotherapy of Cancer with Vaccines Ann NY Acad Sci 690 1993 204 213
15. 2 ganglioside J Clin Oncol 12 1994 1036 1044
16. M. Mitchell W. Harel J. Kan-Mitchell Active specific immunotherapy of melanoma with allogenic cell lysates J.-C. Bystryn S. Ferrone P. Livingston Specific Immunotherapy of Cancer with Vaccines Ann NY Acad Sci 690 1993 153 165
17. M.S. Mitchell D.J. Rechtman K.B. Von Eschen A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma Can J Infect Dis 6 suppl C 1995 347C
18. D. Morton L.J. Foshag D.B.S. Hoon Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 216 1992 463 482
19. R. Oratz C. Cockerall J.L. Speyer Induction of tumor-infiltrating lymphocytes in malignant melanoma metastases by immunization to melanoma antigen vaccine J Biol Res Modif 8 1989 355 358
20. R. Oratz R. Shapiro D. Johnston IL-2 liposomes markedly enhance the activity of a polyvalent melanoma vaccine Proc Am Soc Clin Oncol 15 1996 436
21. S.R. Reynolds R. Oratz R.L. Shapiro Stimulation of CD8+ T cell responses to MAGE-3 and MELAN A/MART-1 by immunization to a polyvalent melanoma vaccine Int J Cancer 72 1997 972 976
22. T. Sato H.C. Maguire M.J. Mastrangelo Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine Clin Immunol Immunopathol 74 1995 35 43
23. M. Wallack M. Sivanandham Clinical trials VMO for melanoma Ann NY Acad Sci 690 1993 178 189